DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Onartuzumab is an investigational drug.
There have been 15 clinical trials for Onartuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Stomach Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and M.D. Anderson Cancer Center.
There are seventeen US patents protecting this investigational drug and five hundred and thirty international patents.
Recent Clinical Trials for Onartuzumab
|An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study||Hoffmann-La Roche||Phase 3|
|Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)||Genentech, Inc.||Phase 1/Phase 2|
|Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)||M.D. Anderson Cancer Center||Phase 1/Phase 2|
Top disease conditions for Onartuzumab
Top clinical trial sponsors for Onartuzumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Onartuzumab||⤷ Try it Free||Multispecific constructs||AbbVie Stemcentrx LLC (North Chicago, IL)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Cancer treatment with c-met antagonists and correlation of the latter with HGF expression||Genentech, Inc. (South San Francisco, CA)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Methods of treating glioblastoma multiforme using ibudilast||MediciNova, Inc. (La Jolla, CA)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Method for predicting efficacy of c-Met inhibitor||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF||SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR)||⤷ Try it Free|
|Onartuzumab||⤷ Try it Free||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Onartuzumab||Canada||CA2900764||2033-02-08||⤷ Try it Free|
|Onartuzumab||European Patent Office||EP2954056||2033-02-08||⤷ Try it Free|
|Onartuzumab||Hong Kong||HK1218930||2033-02-08||⤷ Try it Free|
|Onartuzumab||Japan||JP2016509014||2033-02-08||⤷ Try it Free|
|Onartuzumab||World Intellectual Property Organization (WIPO)||WO2014124326||2033-02-08||⤷ Try it Free|
|Onartuzumab||Australia||AU2013220749||2032-02-15||⤷ Try it Free|
|Onartuzumab||Brazil||BR112014019627||2032-02-15||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|